Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas

Learn more about:
Related Clinical Trial
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas

Official Title

Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas

Brief Summary

      The study intends to examine the association between schistosomiasis seropositivity and
      adverse pregnancy outcomes.

      It aims at the verification of the hypothesis that in pregnant women originating from endemic
      areas for schistosomiasis, positive serology is associated with reduced Infant birth weight.

Detailed Description

      Schistosomiasis is a widespread helminthic infection, with an estimated 249 million people in
      78 countries requiring preventive treatment each year. This infection has a significant
      association with morbidity worldwide. Earlier studies performed in endemic Areas showed that
      the reproductive tract was affected in more than 60% of the women who excreted S. haematobium
      ova in urine. Transplacental transmission has not been observed, but schistosomiasis of the
      pregnant uterus has been reported and placental schistosomiasis has been associated with
      stillbirth. Placental schistosomiasis (i.e. detection of schistosomiasis eggs in placental
      tissue) has been reported occasionally. Schistosomiasis has been postulated to be associated
      with premature delivery and low birth weight; however, existing data are inconsistent.

      Migration to the European Union was estimated at 1.7 million people in 2012. Migrants were
      predominantly from Africa and Asia. In these areas schistosomiasis has an estimated
      prevalence of 10-20%. While a large number of migrants from schistosomiasis-endemic areas
      enter Europe and receive Access to health care, many of them are unaware of helminthic
      infections they may have been exposed to, and their potential outcomes.

      Treatment of schistosomiasis during pregnancy is a matter of debate. The German society for
      tropical medicine recommends treatment with praziquantel only after the completion of
      pregnancy. Conversely, the South African Medicines Formulary suggests that pregnant women
      should be offered treatment individually and that they should not necessarily be excluded
      during treatment campaigns. By quantifying the effects of Schistosoma infection on pregnancy
      outcomes this study will help clinicians in deciding on the question of treatment during

      The aim of the study is to examine the association of maternal schistosomiasis on adverse
      birth outcomes (as defined by low birth weight, premature delivery or stillbirth) in migrants
      to Europe from schistosomiasis endemic areas.

Study Type


Primary Outcome

Schistosoma antibodies

Secondary Outcome

 Birth weight




Specimen collection


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

June 1, 2017

Completion Date

August 31, 2018

Primary Completion Date

May 31, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Pregnancy

          -  Immigration from a country/geographic area with declared endemic schistosomiasis
             according to World Health Organization criteria

          -  Signed informed consent

        Exclusion Criteria:

          -  Placenta pathology of any cause

          -  Any medical condition affecting fetal growth




18 Years - N/A

Accepts Healthy Volunteers



Benjamin Schleenvoigt, M.D., +4936419324670, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Jena University Hospital


 St. Vincent's University Hospital, Dublin, Ireland

Study Sponsor

Benjamin Schleenvoigt, M.D., Principal Investigator, Center for Infectious Diseases and Infection Control, Jena University Hospital

Verification Date

May 2017